High Times
Home > Boards > US OTC > Biotechs >

Mymetics Corporation (MYMX)

Add MYMX Price Alert      Hide Sticky   Hide Intro
Moderator: TheHungryHippo, corpus
Search This Board: 
Last Post: 10/20/2018 10:19:34 PM - Followers: 72 - Board type: Free - Posts Today: 19






Mymetics Corporation is US registered biotechnology company with its main offices in Switzerland and the Netherlands.
Focused on developing next generation preventative vaccines for infectious diseases.
Mymetics core technology and expertise are in the use of virosomes,
lipid-based carriers containing functional fusion viral proteins in combination with rationally designed antigens and membrane proteins.

Objective: "Build small / medium size innovative R&D virosome vaccine company with strong 
partnerships, Phase II – III clinical vaccine pipeline and have optionality for M&A or sale."


Current Share Structure:

Outstanding Shares: 303.7 million (03/2018 unchanged since 2014)
Floating Shares: 79.8 million*  (a/o 03/31/18)



Current Projects and Pipeline


Rationale and Impact of MACIVIVA

With few exceptions, commercialized vaccines are generally delivered by injection through the intramuscular or subcutaneous route.
Vaccines contain immunogens classically found within a large variety of biological compounds such as peptides, proteins, glycoproteins and sometimes carbohydrates and lipids.
These immunogens may trigger the immune system for producing antibodies and/or cytotoxic T cells for preventing the pathogen transmission or blocking and/or slowing down the disease progression.

However, these vaccines generally exist as liquid formulation that are inherently prone to physical and/or chemical modifications. The cold chain storage is still fundamental for preserving the
bioactivity of most liquid and freeze-dried vaccines. For reconstituted freeze dried vaccines, they harbor important instability and must be used within hours and kept refrigerated. Vaccine degradation generally takes place
during shipment and/or storage of liquid or lyophilized products, which may affect the immunological properties of the immunogens, with unwanted immune responses or insufficient immune protection.
There is growing evidence that solid dosage formats (e.g. powder form) for vaccines may offer several advantages over the liquid formulations, such as the prevention of molecular motion and shear-induced degradation,
and slowing down modifications and degradation reactions involving water and oxygen radicals, resulting in improved stability, enhanced shelf-life of vaccines and greatly simplified logistics.

Toward cold chain free vaccines

Today, no commercial vaccine has been developed yet under thermostable solid form (cold chain independent)
for direct nasal or oral delivery (ex. intranasal powder delivery or sublingual pills) without the need of reconstitution with a liquid.


Expertise: R&D on virosome formulations

Project responsability: Investigating and compiling the results about the physical and biochemical properties of the virosome-based vaccines obtained by spray-drying and lyophilization.

Expertise : Non-GMP and GMP virosome production, clinical development

Project responsability: Excipient selection for liquid virosomes, supervising the non-GMP and GMP manufacturing of the liquid virosomes and development of analytical methods.

Expertise: Non-GMP and GMP Spray drying

Project responsability: Identification of excipients and experimental conditions suitable for virosome spray drying, production of non-GMP and GMP powder forms for nasal and oral delivery.

Expertise: Zydis technology for fast-dissolving tablet, world leader in drug formulation and distribution

Project responsability: Identification of excipients and experimental conditions suitable for virosome lyophylization, according to the Zydis technology, non-GMP and GMP tablets for sublingual delivery.

Expertise: Ultra sensitive immunoassays development and bioanalysis based on Imperacer® (Immuno-PCR) technology.

Project responsability: Immunogenicity study in animals with spray-dried and lyophilized virosomes. Imperacer® immunoassay development and evaluation of the vaccine-induced antibody response.

Expertise: R&D, non-GMP and GMP manufacturing of API, world supplier

Project responsability: Process Development and manufacture of peptide P1, GMP-grade, including development and validation of analytical methods.


PXTHERAPEUTICS announces the successful completion of RGP41 GMP manufacturing for Mymetics  

Grenoble, France, and Epalinges, Switzerland, December 12th, 2017 – PXTherapeutics, a CDMO specializing in the development of recombinant proteins for human and animal health, is proud to announce the end of the rgp41 manufacturing campaign and batch certification for clinical application. This drug substance will be used by Mymetics to develop a new vaccine formulation, within the framework of the MACIVIVA project, sustained by the European Union’s Horizon 2020 research and innovation program and the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. 

Rgp41 protein is one of the HIV-1 gp41 derived antigens constituting Mymetics’ HIV-1 vaccine that is anchored to the membrane surface of the virosome particle, which acts as vaccine delivery vehicle for soliciting the immune system for inducing the production of protective serum and mucosal antibodies. 

PXTherapeutics and Mymetics joined forces several years ago to work on rgp41 protein design and development of the production and purification processes of the molecule. PX teams managed to develop an efficient, scalable and GMP-compliant process. A clinical batch was produced from a scale fermentation volume of 120 L to deliver a sufficient quantity for formulation studies and clinical trials. 

Claire Untereiner, Chief Operating Officer of PXTherapeutics, commented as follows: “We are so happy to see the progress made with this molecule and to be part of this fantastic project. MACIVIVA’s objective, the development of cold-chain independent and virosome-based vaccines, responds to a real medical need, particularly in emerging countries, and is in line with PXTherapeutics’ mission, to support and accelerate the development of innovative medicines”. 

Sylvain Fleury, Chief Scientific Officer of Mymetics SA commented: “we are pleased that PXTherapeutics could address many technical challenges related to the GMP development of the recombinant rgp41 protein and achieve a production yield superior to our expectations. With this rgp41, Mymetics will further pursue the development of its HIV-1 candidate vaccine, which could be administered through various immunization routes, as a standalone product or combined with viral vectors in a prime-boost approach”. 


Vaccines are poorly accessible in developing countries

Vaccines require cold-chain storage and are often delivered by injection, which is undesirable, less safe and more expensive to administer.
Developing thermostable solid form vaccines through non-invasive routes may represent a long-term global solution to the vaccination challenge (Amorij, 2008).

Virosomes are an efficient vaccine delivery system

Virosomes are spherical, unilamellar lipid-based carriers, intercalated with functional glycoproteins to reflect the natural virus, however the lack of viral RNA means there is no risk of infection
(Figure 1). Virosomes can be tagged with different antigens and adjuvants, meaning they can be tailored to target different viruses, and offer increased immunogenicity over inactivated viruses.
Currently, virosomal influenza vaccines are only available in liquid form (Amorij, 2008).

Spray drying can produce dry powders for a range of dosage forms, including inhaled or nasal drug delivery.

A dry powder is formed when a liquid feed solution or suspension is atomised using a spray nozzle, and rapidly dried using hot air. However, while the drying process is gentle due to evaporative cooling,
there is still the potential to stress and inactivate vaccine components. It has been found that subunit and live-attenuated vaccines (and other delicate molecules such as proteins)
can be protected during processing b by incorporating them in an amorphous sugar matrix, which also offers longer term stability during storage (Kanojia, 2016).

A method has been developed to produce a powder form of virosome based influenza vaccine using spray-drying.

Formulations have been optimised for oral and nasal delivery.

Advantages of Virosomal Drug Delivery

         Virosomal technology is approved by the FDA for use in humans, and has a high safety profile
         Virosomes are biodegradable, biocompatible, and non-toxic12
         No disease-transmission risk
         No autoimmunogenity or anaphylaxis10
         Broadly applicable with almost all important drugs (anticancer drugs, proteins, peptides, nucleic acids, antibiotics, fungicides)
         Enables drug delivery into the cytoplasm of target cell
         Promotes fusion activity in the endolysosomal pathway
         Protects drugs against degradation


Virosomal Structure and Modifications

Image result for influenza virosome images

Figure 1: Virosomes are reconstituted influenza virus envelopes devoid of inner core and genetic information
Virosomes are spherical unilamellar vesicles with a mean diameter of around 150 nm. Influenza virus is most commonly used for virosome production. Virosomes cannot replicate but are pure fusion-active vesicles. In contrast to liposomes, vorosomes contain functional viral envelope glycoproteins: influenza virus hemagglutinin (HA) and neuraminidase (NA) are intercalated within the phospholipid bilayer membrane (Figure 1). Further characteristics of virosomes depend on the choice of bilayer components. Virosomes can be optimized for maximal incorporation of the drug, or for the best physiological effect by modifying the content or type of membrane lipids used. It is even possible to generate carriers for antisense-oligonucleotides or other genetic molecules, depending on whether positively or negatively loaded phospholipids are incorporated into the membrane. Various ligands, such as cytokines, peptides, and monoclonal antibodies (MAbs) can be incorporated into the virosome and displayed on the virosomal surface. Even tumor-specific monoclonal antibody fragments (Fab) can be linked to virosomes to direct the carrier to selected tumor cells.1,11

Intellectual  Property

WO/1999/025377 (GP41 mutee) Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection Mymetics Corp. Expiration date: November 16, 2018
WO/2005/010033 (GP41 ter) New soluble and stabilized trimeric form of GP 41 polypeptide Mymetics Corp. Expiration date: July 28, 2024
WO/2007/099446 (Virosome-P1) Virosome-like vesicles comprising gp41 - derived antigens Mymetics Corp. + INSERM + Pevion Expiration date: January 3, 2027

US/61/202 215 (GP41 4th gen) Mymetics Corp. Expiration date: February 5, 2029
US/61/202 219 (Splitting GP41) Mymetics Corp. Expiration date: February 5, 2029
WO/2004/106366 (UK39) Methods for synthetizing conformationally constrained peptides, peptidomimetics and use of such peptidomimetics as synthetic vaccines Mymetics Corp. Expiration date: June 1, 2024
WO/2004/078099 (AMA49) Compositions and methods for the generation of immune response against Malaria Mymetics Corp. Expiration date: March 2, 2023
WO/2004/045641 (APRECS) Antigen-complexes Bestewil BV Expiration date: November 19, 2023
WO/2004/110486 (Lipopeptide) Functionally reconstituted viral membranes containing adjuvant Bestewil BV Expiration date: June 17, 2024
WO/2004071492 (DCPC) Virosome-like particles Bestewil BV Expiration date: December 2, 2023
  [Viruses that can be applied and used in the formation of the virosome-like-particles according to the invention can be derived from all sorts of viruses, non-limiting examples of     such viruses being: Retroviridae such as Human Immunodeficiency virus (HIV); rubellavirus; paramyxoviridae such as parainfluenza viruses, measles, mumps, respiratory syncytial virus, human metapneumovirus; flaviviridae such as yellow fever virus, dengue virus, Hepatitis C Virus (HCV), Japanese Encephalitis Virus (JEV), tick-borne encephalitis, St. Louis encephalitis or West Nile virus; Herpesviridae such as Herpes Simplex virus, cytomegalovirus, Epstein-Barr virus; Bunyaviridae; Arenaviridae; Hantaviridae such as Hantaan; Coronaviridae; Papovaviridae such as human Papillomavirus; Rhabdoviridae such as rabies virus. Coronaviridae such as human coronavirus; Alphaviridae, Arteriviridae, filoviridae such as Ebolavirus, Arenaviridae, poxyiridae such as smallpox virus, and African Swine Fever virus.]  








High Times
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MYMX News: Quarterly Report (10-q) 08/13/2018 09:06:12 AM
MYMX News: Quarterly Report (10-q) 05/14/2018 02:13:13 PM
MYMX News: Current Report Filing (8-k) 04/23/2018 06:11:53 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#9228  Sticky Note MYMX VACCINE COMPANY OVERVIEW TheHungryHippo 10/06/18 01:28:07 PM
#5685  Sticky Note Copy of MACIVIVA Presentation at World Vaccine Congress corpus 01/09/18 12:36:16 PM
#10029   https://www.frontiersin.org/files/Articles/333832/fimmu-09-00600-HTML-r1/image_m bow-tie 10/20/18 10:19:34 PM
#10028   https://www.researchgate.net/figure/Intellectual-property-related-to-influenza-v bow-tie 10/20/18 09:53:31 PM
#10027   Ok Staypositive1 10/20/18 05:27:40 PM
#10026   They work, try clearing your cache Work Harder 10/20/18 05:26:55 PM
#10025   Those gov sites dont work. Staypositive1 10/20/18 05:24:09 PM
#10024   So if someone splits gp41 into rgp41 we Staypositive1 10/20/18 05:23:07 PM
#10023   LVAC-HIV (vCP2438) is a preparation of live attenuated Work Harder 10/20/18 05:03:47 PM
#10022   Among the conserved neutralizing epitopes of Env the Work Harder 10/20/18 03:27:07 PM
#10021   Aventis Pasteur, new name of Pasteur Mérieux now Sanofi Work Harder 10/20/18 02:45:39 PM
#10020   But we were here first. https://www.iex.nl/Forum/Topic/1085237/Crucell_Mymetics Staypositive1 10/20/18 01:35:55 PM
#10019   Then we are here. https://www.eurekalert.org/pub_releases/2016-04/tbri-mhv04081 Staypositive1 10/20/18 01:34:39 PM
#10018   So the whole thing started here. https://www.google.com/url?sa=t&source=web&rct Staypositive1 10/20/18 01:32:18 PM
#10017   Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection bow-tie 10/20/18 10:18:04 AM
#10016   Getting closer n closer Work Harder 10/20/18 10:11:21 AM
#10015   † Present address: International AIDS Vaccine Initiative, 110 bow-tie 10/20/18 10:06:20 AM
#10014   & now a new strain in Canada Work Harder 10/20/18 10:04:22 AM
#10013   I believe we are in good hands Work Harder 10/20/18 09:49:09 AM
#10012   I read that also which is why the Staypositive1 10/20/18 09:46:39 AM
#10011   HIV clades also vary in prevalence throughout the Work Harder 10/20/18 09:33:21 AM
#10010   https://aidsinfo.nih.gov/search?q=clade[space]c[space]gp41&c=site bow-tie 10/19/18 11:38:08 PM
#10009   https://aidsinfo.nih.gov/contentfiles/glossaryhivrelatedterms_english.pdf bow-tie 10/19/18 11:09:14 PM
#10008   Broadly Neutralizing Antibodies and the Promise of Universal Vaccines bow-tie 10/19/18 11:06:23 PM
#10007   namely 4-2.J41, isolated from an Indian patient. Work Harder 10/19/18 09:44:56 PM
#10006   Clade C, why? Work Harder 10/19/18 09:36:11 PM
#10005   Isn't that interesting friend Work Harder 10/19/18 09:31:54 PM
#10004   Trimetric....huh who has that patent https://patents.justia.com/patent/20080213 Staypositive1 10/19/18 08:37:56 PM
#10003   What say U B Dog Work Harder 10/19/18 08:03:03 PM
#10002   Appreciate his efforts but Work Harder 10/19/18 07:28:22 PM
#10001   & glade C Work Harder 10/19/18 07:27:27 PM
#10000   Same paper & authors in Portugal Work Harder 10/19/18 07:22:27 PM
#9999   https://patentimages.storage.googleapis.com/78/3b/0f/7943680e1c743e/US8652459.pd Staypositive1 10/19/18 07:18:54 PM
#9998   How's that weekly looking to ya Work Harder 10/19/18 07:15:41 PM
#9997   Our patents specifically clade B friend. Checked Staypositive1 10/19/18 07:15:18 PM
#9996   I hope this finds you well my friend Work Harder 10/19/18 07:05:22 PM
#9995   Three AIDS Scientists Win NIH Funding for These Work Harder 10/19/18 03:11:45 PM
#9994   Covalent stabilization of coiled coils of the HIV Work Harder 10/19/18 02:23:53 PM
#9993   T20 peptide (enfuvirtide) is the first U.S. FDA-approved Work Harder 10/19/18 02:07:43 PM
#9992   Gilead's HIV Franchise Under Assault As It Stares Work Harder 10/19/18 01:54:20 PM
#9991   https://twitter.com/UppertonLtd/status/1053285339316609024 Phosphene 10/19/18 01:41:20 PM
#9990   transmembrane gp41 from clade B, and Gag/Pro from Work Harder 10/19/18 01:19:18 PM
#9989   I'd say that small research project w/ Sanofi Work Harder 10/19/18 01:09:06 PM
#9988   U suppose that was what they were talking about? Staypositive1 10/19/18 01:03:16 PM
#9987   Enrollment for HVTN 703/HPTN 081 (sub-Saharan African women) Work Harder 10/19/18 12:53:12 PM
#9986   Sanofi is manufacturing the trispecific antibody for use Work Harder 10/19/18 12:46:38 PM
#9985   Sanofi Hiv direct interest in gp41 Work Harder 10/19/18 12:28:58 PM
#9984   Yeow, I learned something Work Harder 10/19/18 10:35:46 AM
#9983   Much gratitude for the shared article amigo. Phosphene 10/19/18 10:25:10 AM
#9982   It's unlikely, however Ablynx that Sanofi Work Harder 10/18/18 11:00:07 PM
#9981   Could they be talking about us here at all? https://twitter.com/CatalentPharma/ Staypositive1 10/18/18 07:50:44 PM
#9980   This is a fantastic Board. It was a 46er 10/18/18 07:33:22 PM